Entact Bio

Entact Bio is a preclinical stage biotechnology company based in Boston. It is developing a new class of drugs that enhance the function of beneficial proteins by harnessing deubiquitinase (DUB) biochemistry via heterobifunctional, enhancement-targeting chimeric (ENTAC™) medicines. ENTACs harness the ability of DUBs to regulate proteins.